CD274 and non-small cell lung carcinoma: Increasing evidence shows that NSCLC in patients with PD-L1 overexpression (TPS > 50%) is significantly related to tobacco smoking, and these patients experience better responses to immunotherapy with PD-L1 inhibitors [19,20].